Logo

CombiMatrix to Get $1.5M from Sale of Securities

Jan 12, 2009

NEW YORK (GenomeWeb News) – CombiMatrix said Friday after the close of the market that all of its $1.5 million worth of auction rate securities were recently liquidated.

Last year, the Mukilteo, Wash.-based firm had said that those securities had become illiquid due to the global financial credit crisis. CombiMatrix is one of many firms that faced similar losses as the auction rate security market froze up. However, several investment banks that had participated in the distribution of auction rate securities agreed last year to buy back billions of dollars worth of the debt instruments.

Amit Kumar, president and CEO of CombiMatrix, said in a statement that the firm would use the $1.5 million to expand its diagnostics business.

A company spokesperson declined to provide further details.

Filed under

Diagnostics
Microarrays & Multiplexing
microarrays
Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.